On November 13, 2025, Kura Oncology (Kura) and Kyowa Kirin announced that the U.S. Food and Drug Administration (FDA) has granted full approval for KOMZIFTI™ (ziftomenib). Wilson Sonsini Goodrich & Rosati advised Kura on patent and trademark matters.

KOMZIFTI (ziftomenib) is an oral menin inhibitor approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. FDA approval is supported by the pivotal KOMET-001 trial (NCT04067336), which evaluated KOMZIFTI’s safety and efficacy in 112 R/R NPM1-m AML patients.

The Wilson Sonsini team that advises Kura on patent and trademark matters includes Ingo Hardt, Karen Wong, Aaron Hendelman, Jim Malecha, and Michael Wormald.

For more information, please see Kura’s news release. Additional coverage can be found on Fierce Pharma.